Providing a focal point to push industry collaboration through updates on clinical advancements and investment opportunities, SMi presents the 20th annual Superbugs & Superdrugs conference which will return to Central London on 19th and 20th March 2018.
The threat of AMR is regularly making front page news but what is the industry actually doing? Are drug manufacturers any closer to finding a solution and how is the government helping? These will be just some of the questions answered through powerful keynote addresses delivered by an expert panel of scientific leaders, drug discovery specialists and government bodies such as MHRA and DNDi.
SMi Group's Superbugs and Superdrugs USA 2018Dale Butler
This document provides information on the 3rd annual Superbugs & Superdrugs USA conference taking place November 12-13, 2018 in Iselin, New Jersey. Anthony Simon Lynch and William Weiss will chair the event. Featured speakers will discuss topics such as pathogen-focused drug development, antibiotic resistance, novel modes of action to overcome resistance, and new anti-fungal developments. Participants will learn about funding opportunities, rapid diagnostic methods, and case studies. Two half-day workshops on November 14 will focus on rapid diagnostics for drug resistance and challenges of commercializing new antibiotics. SCYNEXIS, Inc. is sponsoring the conference.
This document summarizes an upcoming conference on superbugs and superdrugs taking place March 25-26, 2015 in London. The conference will focus on the latest developments in antibacterial therapies, funding, and partnerships to address antibiotic resistance. Over the two days, the conference will feature speakers from industry and academia discussing topics such as new business models for antibiotic development, clinical trials of new treatments, and partnerships between government and private organizations. Attendees can choose from two pre-conference workshops on designing antimicrobials for future needs and licensing an antibiotic. The conference is aimed at professionals involved in antibiotic research, development and related fields.
SMi Group's Superbugs and Superdrugs 2020 conferenceDale Butler
This document provides information about the Superbugs & Superdrugs conference on March 30-31, 2020 in London. The conference will focus on non-traditional approaches to fighting antimicrobial resistance and will feature speakers from companies and organizations working on alternatives to antibiotics, including those developing antibacterial proteins, agents that neutralize bacterial virulence, direct lytic agents, and immunomodulatory therapies. It provides details on the agenda, speakers, workshops, registration and sponsorship opportunities.
This document provides information about an upcoming conference on immunogenicity taking place June 13-14, 2016 in London. It lists the schedule, speakers, and topics to be covered over the two days. The conference will explore approaches to standardizing immunogenicity assays, unwanted immunogenicity, integrating immunogenicity risk data to predict clinical outcomes, and other topics related to assessing and reducing the immunogenicity of biotherapeutics. Registration discounts are available by March 31st or April 29th. The conference is aimed at accelerating the commercialization of next generation biotherapeutics by adopting advanced immunogenicity assessments.
This document provides information about the 4th Annual Conference on Cancer Vaccines to be held on September 16-17, 2015 in London. Professor Farzin Farzaneh of Kings College London will chair the conference. Key topics to be addressed include tumour genetic heterogeneity in immunotherapy, combination therapies to advance immune-oncology vaccines, and developments in targeted and personalized cancer treatments. There will be presentations from industry and academic leaders in the field.
Lighting Rockets at the UChicago Microbiome LaunchpadLaura Berry
Presented at the 5th Microbiome R&D and Business Collaboration Forum: USA. To find out more, visit:
www.global-engage.com
With the recent gift of $100 million, the Duchossois Family Institute was established, providing UChicago with the resources to develop models for translating microbiome research. Matt Martin discusses their plans for expanding the support provided to faculty and the mechanisms for launching their startups and technologies.
This document provides an overview and agenda for the 2nd annual conference on drug discovery taking place on March 21st-22nd, 2018 in London. The conference will feature presentations and discussions on:
1) New technologies to improve discovery cycles in chemistry and drug discovery processes, including the role of artificial intelligence and new modalities like PROTACs and antibodies.
2) Advances in small molecule therapeutics from Roche and challenges in validating targets with CRISPR from Epizyme.
3) The role of open access chemical probes from the SGC and how Bayer uses them in drug discovery.
4) How artificial intelligence can transform drug design and discovery efforts at companies like Exscient
SMi Group's Superbugs and Superdrugs USA 2018Dale Butler
This document provides information on the 3rd annual Superbugs & Superdrugs USA conference taking place November 12-13, 2018 in Iselin, New Jersey. Anthony Simon Lynch and William Weiss will chair the event. Featured speakers will discuss topics such as pathogen-focused drug development, antibiotic resistance, novel modes of action to overcome resistance, and new anti-fungal developments. Participants will learn about funding opportunities, rapid diagnostic methods, and case studies. Two half-day workshops on November 14 will focus on rapid diagnostics for drug resistance and challenges of commercializing new antibiotics. SCYNEXIS, Inc. is sponsoring the conference.
This document summarizes an upcoming conference on superbugs and superdrugs taking place March 25-26, 2015 in London. The conference will focus on the latest developments in antibacterial therapies, funding, and partnerships to address antibiotic resistance. Over the two days, the conference will feature speakers from industry and academia discussing topics such as new business models for antibiotic development, clinical trials of new treatments, and partnerships between government and private organizations. Attendees can choose from two pre-conference workshops on designing antimicrobials for future needs and licensing an antibiotic. The conference is aimed at professionals involved in antibiotic research, development and related fields.
SMi Group's Superbugs and Superdrugs 2020 conferenceDale Butler
This document provides information about the Superbugs & Superdrugs conference on March 30-31, 2020 in London. The conference will focus on non-traditional approaches to fighting antimicrobial resistance and will feature speakers from companies and organizations working on alternatives to antibiotics, including those developing antibacterial proteins, agents that neutralize bacterial virulence, direct lytic agents, and immunomodulatory therapies. It provides details on the agenda, speakers, workshops, registration and sponsorship opportunities.
This document provides information about an upcoming conference on immunogenicity taking place June 13-14, 2016 in London. It lists the schedule, speakers, and topics to be covered over the two days. The conference will explore approaches to standardizing immunogenicity assays, unwanted immunogenicity, integrating immunogenicity risk data to predict clinical outcomes, and other topics related to assessing and reducing the immunogenicity of biotherapeutics. Registration discounts are available by March 31st or April 29th. The conference is aimed at accelerating the commercialization of next generation biotherapeutics by adopting advanced immunogenicity assessments.
This document provides information about the 4th Annual Conference on Cancer Vaccines to be held on September 16-17, 2015 in London. Professor Farzin Farzaneh of Kings College London will chair the conference. Key topics to be addressed include tumour genetic heterogeneity in immunotherapy, combination therapies to advance immune-oncology vaccines, and developments in targeted and personalized cancer treatments. There will be presentations from industry and academic leaders in the field.
Lighting Rockets at the UChicago Microbiome LaunchpadLaura Berry
Presented at the 5th Microbiome R&D and Business Collaboration Forum: USA. To find out more, visit:
www.global-engage.com
With the recent gift of $100 million, the Duchossois Family Institute was established, providing UChicago with the resources to develop models for translating microbiome research. Matt Martin discusses their plans for expanding the support provided to faculty and the mechanisms for launching their startups and technologies.
This document provides an overview and agenda for the 2nd annual conference on drug discovery taking place on March 21st-22nd, 2018 in London. The conference will feature presentations and discussions on:
1) New technologies to improve discovery cycles in chemistry and drug discovery processes, including the role of artificial intelligence and new modalities like PROTACs and antibodies.
2) Advances in small molecule therapeutics from Roche and challenges in validating targets with CRISPR from Epizyme.
3) The role of open access chemical probes from the SGC and how Bayer uses them in drug discovery.
4) How artificial intelligence can transform drug design and discovery efforts at companies like Exscient
We have 13 research and development projects within:
• Research
• Oncology
• Respiratory, Inflammation and Autoimmunity
• Cardiovascular and Metabolic Disease
• Antibody Discovery and Protein Engineering
• Pathology
• Biopharmaceutical Development
• Cell Culture and Fermentation Sciences
• Formulation Sciences
• Analytical Biotechnology Science
This document summarizes PCT's vision and history as a leader in cell therapy manufacturing. PCT aims to make transformative cell-based therapies accessible to all through providing high-quality and scalable manufacturing services. Over 30 years, PCT has gained unprecedented expertise manufacturing over 20 cell therapy products and treating over 6,000 patients. PCT partners with companies from start-ups to large pharmaceutical companies, and aims to guide clients through the entire development and manufacturing process.
Domainex, a contract research organization, announced a collaboration with Sigma-Aldrich to advance the study of epigenetic proteins involved in cancer and stem cell biology. Through the collaboration, Domainex will use its protein expression technology to produce domains of epigenetic proteins to develop biochemical assays, while Sigma-Aldrich will use the proteins to develop monoclonal antibodies. These tools will help researchers study the function of these important proteins. Funding from the UK Technology Strategy Board will support the work.
Vaxeal is a biopharmaceutical company developing therapeutic cancer vaccines and treatments for infectious diseases. It has several vaccine candidates in pre-clinical development targeting cancers and hepatitis C that are expected to begin clinical trials in Europe in 2014-2015. Vaxeal takes promising early-stage research from academic partners and advances it through clinical proof-of-concept, with the goal of improving patient access to new treatments.
Antibiotic Guardian London Workshop 20164 All of Us
Antibiotic resistance is one of the biggest threats facing us today.
Why it is relevant to you: without effective antibiotics many routine treatments will become increasingly dangerous. Setting broken bones, basic operations, even chemotherapy and animal health all rely on access to antibiotics that work.
What we want you to do: To slow resistance we need to cut the unnecessary use of antibiotics. We invite the public, students and educators, farmers, the veterinary and medical communities and professional organisations, to become Antibiotic Guardians.
Call to action: Choose one simple pledge about how you’ll make better use of antibiotics and help save these vital medicines from becoming obsolete.
- Neusentis is a regenerative medicine subsidiary of Pfizer focused on developing cell-based therapies.
- Their portfolio includes collaborations on stem cell-derived retinal pigment epithelial (RPE) cells to treat macular degeneration, and allogenic adult multipotent stem cells to treat inflammatory bowel disease.
- Major challenges for developing and commercializing cell therapies include cell biology and manufacturing complexities, rigorous clinical trial design and supply logistics, and demonstrating a clear business case for pricing and reimbursement.
This document provides information about the Cell & Gene Therapy conference taking place on October 10-11, 2018 in London. It includes details about the agenda, speakers, workshops, and registration information. The two-day conference will focus on topics related to manufacturing, regulation, and translational research of cell and gene therapies. There will be presentations from industry experts on developing stem cell and gene therapies, as well as workshops on practical development issues and competitive intelligence in the cell and gene therapy field.
In its third year, “PEGS China: Protein and Antibody Engineering & Development Summit” returns to Shanghai for 3 days of inspiring presentations and case studies featuring the latest trends and future potential of China’s biotech industry.
This year’s event comprises four content-driven conferences with over sixty global speakers, plus a new 1-day seminar on clinical & regulatory strategies for global and domestic IND and BLA filings. In addition, dedicated exhibit hall and poster viewing hours will provide invaluable opportunities for networking, deal-making and ideas exchange.
Innovation and entrepreneurship in biotechnology an intl perspective - d. h...sanguru1977
This document provides an introduction to innovation and entrepreneurship in biotechnology. It defines innovation as new products, services, processes or ideas that are novel to an organization. Innovation can take various forms, including technological versus non-technological, and product versus process innovation. The document scopes the focus of the book, which is on entrepreneurship and innovation processes that are important for new biotechnology firms. It emphasizes the importance of innovation and entrepreneurship for competitiveness in the biotechnology industry.
This document provides information about the "Vaccine Research & Innovation 2010" conference taking place on September 2-3, 2010 in London. The conference will explore opportunities in vaccine research and development and feature key speakers from companies such as Novartis Vaccines, Merck, and Intercell. Attendees will gain insights into topics like overcoming challenges in cancer vaccine development, evaluating immune responses to combination vaccines, and implementing strategies for manufacturing conjugate vaccines. The conference is designed to share successful strategies and innovative technologies for developing more effective vaccines.
Webinar: Re-imagining vaccine manufacturing to address global health challengesMilliporeSigma
Participate in the interactive on demand webinar: http://bit.ly/ReimaginingVaccinesWebinar
In this webinar, you will learn:
- The evolution of vaccine production in response to pandemics and outbreaks
- Key considerations and perspectives on how vaccine processing and facilities could change to address future global health challenges
Sponsor Day on animal feeding: Animal production without antibiotics. Where a...Irta
This document discusses alternatives to antibiotic use in animal production. It begins by reviewing the history of antibiotic resistance, current antibiotic usage levels in Europe, and reasons antibiotics are commonly used. It then describes initiatives like the European Innovation Partnership to promote innovation. One focus group examined alternatives to antibiotics under three headings: attitudes and information, general animal health and welfare improvements, and specific alternatives. Recommendations included benchmarking systems, economic evaluations, biosecurity improvements, vaccination, and zinc or prebiotic supplementation.
This document summarizes key information about biological drugs and biosimilars, including:
1) It defines biologicals as drugs derived from biological sources using biotechnology like recombinant DNA or monoclonal antibody techniques. Biologicals have higher molecular weights and more complex structures than traditional drugs.
2) Immunogenicity, or the potential to provoke an immune response, is a major difference between biologicals and traditional drugs and can reduce efficacy of biologicals.
3) Several studies found biosimilars of biological drugs like alpha interferon and alpha erythropoietin showed differences in quality, efficacy, and safety compared to reference products in some cases.
4) Antibodies developed against biologicals can
SMi is proud to present the 2017 19th annual Superbugs & Superdrugs conference, taking place on 20th and 21st March in Central London.
Expanding horizons on the growing threat of anti-microbial resistance for almost two decades, the flagship show in the global Superbugs portfolio of events will once again play host to an international audience of scientific leaders, funding bodies and drug discovery specialists, providing a focal point to push industry collaboration through updates on clinical advancements and investment opportunities.
This document provides information on two pre-conference workshops at the "Superbugs & Superdrugs" conference on combating antimicrobial resistance.
The first workshop discusses rapid diagnostic tools for infectious diseases, focusing on tracking emerging infections, state-of-the-art diagnostic methods, mobile applications, and challenges in diagnosis.
The second workshop examines how antimicrobial copper touch surfaces can improve patient outcomes and reduce costs by lowering healthcare-associated infections and antimicrobial resistance. It will evaluate the evidence supporting copper's use and discuss cost-benefit analysis and practical implementation.
This document provides information on two pre-conference workshops at the "Superbugs & Superdrugs" conference on combating antimicrobial resistance.
The first workshop discusses rapid diagnostic tools for infectious diseases, focusing on tracking emerging infections, state-of-the-art diagnostic methods, mobile applications, and challenges in diagnosis.
The second workshop examines making materials like copper touch surfaces in healthcare settings to improve patient outcomes and reduce costs by lowering infection rates and antimicrobial resistance. It will evaluate the evidence for copper's antimicrobial efficacy and cost-benefit analysis.
This document provides information about an upcoming Immuno-Oncology conference, including workshops, speakers, and program details. The conference will take place September 25-27, 2018 in London and will feature discussions on novel targeted cancer therapies. It will include workshops on strategic intelligence in immuno-oncology and the microbiome's role in cancer immunotherapy. The two-day main conference will discuss topics like immune checkpoints, oncolytic viruses, bispecific antibodies, and combination therapies. It aims to foster thought-provoking discussions in this space.
SMi Group's Superbugs and Superdrugs USA 2016Dale Butler
This document provides information about the "Superbugs & Superdrugs USA" conference happening from November 14-16, 2016. It advertises the opportunity to register for the conference at discounted rates by certain deadlines. The conference will focus on developing new drugs to combat antibiotic resistance and will feature expert speakers from organizations like the WHO, BARDA, NIH, Pfizer and others. An interactive workshop on animal models in pre-clinical drug development will also be held.
This document provides information about an upcoming conference on immunogenicity taking place from June 12-13, 2017 in London. The conference will focus on standardizing immunogenicity methods, regulatory considerations, novel approaches to reducing immunogenicity, developments for biologic drugs and immunogenicity predictions, and emerging solutions. It lists the program agenda with topics such as predictive tools for immunogenicity, reporting clinically relevant data, cut point setting, EU guidance, ADA-dependent reactions, personalizing therapy, tolerogenic nanoparticles, and a panel on human versus humanized antibodies. Speakers are from organizations like Regeneron, NIBSC, EpiVax, Novartis, Abbvie, Merck, Roche, and Immun
We have 13 research and development projects within:
• Research
• Oncology
• Respiratory, Inflammation and Autoimmunity
• Cardiovascular and Metabolic Disease
• Antibody Discovery and Protein Engineering
• Pathology
• Biopharmaceutical Development
• Cell Culture and Fermentation Sciences
• Formulation Sciences
• Analytical Biotechnology Science
This document summarizes PCT's vision and history as a leader in cell therapy manufacturing. PCT aims to make transformative cell-based therapies accessible to all through providing high-quality and scalable manufacturing services. Over 30 years, PCT has gained unprecedented expertise manufacturing over 20 cell therapy products and treating over 6,000 patients. PCT partners with companies from start-ups to large pharmaceutical companies, and aims to guide clients through the entire development and manufacturing process.
Domainex, a contract research organization, announced a collaboration with Sigma-Aldrich to advance the study of epigenetic proteins involved in cancer and stem cell biology. Through the collaboration, Domainex will use its protein expression technology to produce domains of epigenetic proteins to develop biochemical assays, while Sigma-Aldrich will use the proteins to develop monoclonal antibodies. These tools will help researchers study the function of these important proteins. Funding from the UK Technology Strategy Board will support the work.
Vaxeal is a biopharmaceutical company developing therapeutic cancer vaccines and treatments for infectious diseases. It has several vaccine candidates in pre-clinical development targeting cancers and hepatitis C that are expected to begin clinical trials in Europe in 2014-2015. Vaxeal takes promising early-stage research from academic partners and advances it through clinical proof-of-concept, with the goal of improving patient access to new treatments.
Antibiotic Guardian London Workshop 20164 All of Us
Antibiotic resistance is one of the biggest threats facing us today.
Why it is relevant to you: without effective antibiotics many routine treatments will become increasingly dangerous. Setting broken bones, basic operations, even chemotherapy and animal health all rely on access to antibiotics that work.
What we want you to do: To slow resistance we need to cut the unnecessary use of antibiotics. We invite the public, students and educators, farmers, the veterinary and medical communities and professional organisations, to become Antibiotic Guardians.
Call to action: Choose one simple pledge about how you’ll make better use of antibiotics and help save these vital medicines from becoming obsolete.
- Neusentis is a regenerative medicine subsidiary of Pfizer focused on developing cell-based therapies.
- Their portfolio includes collaborations on stem cell-derived retinal pigment epithelial (RPE) cells to treat macular degeneration, and allogenic adult multipotent stem cells to treat inflammatory bowel disease.
- Major challenges for developing and commercializing cell therapies include cell biology and manufacturing complexities, rigorous clinical trial design and supply logistics, and demonstrating a clear business case for pricing and reimbursement.
This document provides information about the Cell & Gene Therapy conference taking place on October 10-11, 2018 in London. It includes details about the agenda, speakers, workshops, and registration information. The two-day conference will focus on topics related to manufacturing, regulation, and translational research of cell and gene therapies. There will be presentations from industry experts on developing stem cell and gene therapies, as well as workshops on practical development issues and competitive intelligence in the cell and gene therapy field.
In its third year, “PEGS China: Protein and Antibody Engineering & Development Summit” returns to Shanghai for 3 days of inspiring presentations and case studies featuring the latest trends and future potential of China’s biotech industry.
This year’s event comprises four content-driven conferences with over sixty global speakers, plus a new 1-day seminar on clinical & regulatory strategies for global and domestic IND and BLA filings. In addition, dedicated exhibit hall and poster viewing hours will provide invaluable opportunities for networking, deal-making and ideas exchange.
Innovation and entrepreneurship in biotechnology an intl perspective - d. h...sanguru1977
This document provides an introduction to innovation and entrepreneurship in biotechnology. It defines innovation as new products, services, processes or ideas that are novel to an organization. Innovation can take various forms, including technological versus non-technological, and product versus process innovation. The document scopes the focus of the book, which is on entrepreneurship and innovation processes that are important for new biotechnology firms. It emphasizes the importance of innovation and entrepreneurship for competitiveness in the biotechnology industry.
This document provides information about the "Vaccine Research & Innovation 2010" conference taking place on September 2-3, 2010 in London. The conference will explore opportunities in vaccine research and development and feature key speakers from companies such as Novartis Vaccines, Merck, and Intercell. Attendees will gain insights into topics like overcoming challenges in cancer vaccine development, evaluating immune responses to combination vaccines, and implementing strategies for manufacturing conjugate vaccines. The conference is designed to share successful strategies and innovative technologies for developing more effective vaccines.
Webinar: Re-imagining vaccine manufacturing to address global health challengesMilliporeSigma
Participate in the interactive on demand webinar: http://bit.ly/ReimaginingVaccinesWebinar
In this webinar, you will learn:
- The evolution of vaccine production in response to pandemics and outbreaks
- Key considerations and perspectives on how vaccine processing and facilities could change to address future global health challenges
Sponsor Day on animal feeding: Animal production without antibiotics. Where a...Irta
This document discusses alternatives to antibiotic use in animal production. It begins by reviewing the history of antibiotic resistance, current antibiotic usage levels in Europe, and reasons antibiotics are commonly used. It then describes initiatives like the European Innovation Partnership to promote innovation. One focus group examined alternatives to antibiotics under three headings: attitudes and information, general animal health and welfare improvements, and specific alternatives. Recommendations included benchmarking systems, economic evaluations, biosecurity improvements, vaccination, and zinc or prebiotic supplementation.
This document summarizes key information about biological drugs and biosimilars, including:
1) It defines biologicals as drugs derived from biological sources using biotechnology like recombinant DNA or monoclonal antibody techniques. Biologicals have higher molecular weights and more complex structures than traditional drugs.
2) Immunogenicity, or the potential to provoke an immune response, is a major difference between biologicals and traditional drugs and can reduce efficacy of biologicals.
3) Several studies found biosimilars of biological drugs like alpha interferon and alpha erythropoietin showed differences in quality, efficacy, and safety compared to reference products in some cases.
4) Antibodies developed against biologicals can
SMi is proud to present the 2017 19th annual Superbugs & Superdrugs conference, taking place on 20th and 21st March in Central London.
Expanding horizons on the growing threat of anti-microbial resistance for almost two decades, the flagship show in the global Superbugs portfolio of events will once again play host to an international audience of scientific leaders, funding bodies and drug discovery specialists, providing a focal point to push industry collaboration through updates on clinical advancements and investment opportunities.
This document provides information on two pre-conference workshops at the "Superbugs & Superdrugs" conference on combating antimicrobial resistance.
The first workshop discusses rapid diagnostic tools for infectious diseases, focusing on tracking emerging infections, state-of-the-art diagnostic methods, mobile applications, and challenges in diagnosis.
The second workshop examines how antimicrobial copper touch surfaces can improve patient outcomes and reduce costs by lowering healthcare-associated infections and antimicrobial resistance. It will evaluate the evidence supporting copper's use and discuss cost-benefit analysis and practical implementation.
This document provides information on two pre-conference workshops at the "Superbugs & Superdrugs" conference on combating antimicrobial resistance.
The first workshop discusses rapid diagnostic tools for infectious diseases, focusing on tracking emerging infections, state-of-the-art diagnostic methods, mobile applications, and challenges in diagnosis.
The second workshop examines making materials like copper touch surfaces in healthcare settings to improve patient outcomes and reduce costs by lowering infection rates and antimicrobial resistance. It will evaluate the evidence for copper's antimicrobial efficacy and cost-benefit analysis.
This document provides information about an upcoming Immuno-Oncology conference, including workshops, speakers, and program details. The conference will take place September 25-27, 2018 in London and will feature discussions on novel targeted cancer therapies. It will include workshops on strategic intelligence in immuno-oncology and the microbiome's role in cancer immunotherapy. The two-day main conference will discuss topics like immune checkpoints, oncolytic viruses, bispecific antibodies, and combination therapies. It aims to foster thought-provoking discussions in this space.
SMi Group's Superbugs and Superdrugs USA 2016Dale Butler
This document provides information about the "Superbugs & Superdrugs USA" conference happening from November 14-16, 2016. It advertises the opportunity to register for the conference at discounted rates by certain deadlines. The conference will focus on developing new drugs to combat antibiotic resistance and will feature expert speakers from organizations like the WHO, BARDA, NIH, Pfizer and others. An interactive workshop on animal models in pre-clinical drug development will also be held.
This document provides information about an upcoming conference on immunogenicity taking place from June 12-13, 2017 in London. The conference will focus on standardizing immunogenicity methods, regulatory considerations, novel approaches to reducing immunogenicity, developments for biologic drugs and immunogenicity predictions, and emerging solutions. It lists the program agenda with topics such as predictive tools for immunogenicity, reporting clinically relevant data, cut point setting, EU guidance, ADA-dependent reactions, personalizing therapy, tolerogenic nanoparticles, and a panel on human versus humanized antibodies. Speakers are from organizations like Regeneron, NIBSC, EpiVax, Novartis, Abbvie, Merck, Roche, and Immun
Healthcare-associated infections are a major public health problem worldwide and a leading cause of death in hospitals. Antimicrobial resistance poses a serious threat as many antibiotics are becoming ineffective. Disinfection and sanitization are important first lines of defense against disease-causing microbes. However, research and development of new and effective disinfectants has been limited by a lack of funding and public perception of disinfectants as non-essential. Increased investment in disinfectant research and ensuring proper use and training are needed to address the growing risks of antibiotic resistance.
This document provides information about the 4th annual ADC Summit 2015 conference organized by SMi that will take place from May 18-19, 2015 in London. The conference will focus on advancing antibody-drug conjugate (ADC) and radioimmunotherapy (RIT) therapies, with sessions on payload development, clinical trials of ADCs, small molecule approaches, and intellectual property issues. There will also be a half-day workshop on May 20 about the regulatory requirements and development process for ADCs.
This document provides information about an upcoming conference on immunogenicity to be held June 13-14, 2016 in London. It includes an overview of the conference sessions and speakers. The sessions will cover topics such as approaches to standardizing drug level and anti-drug antibody assays, unwanted immunogenicity, integrating immunogenicity risk data, immunogenicity of biologics and biosimilars, and the role of aggregation in immunogenicity. There will also be two half-day post-conference workshops on June 15 on standardizing assays for biotherapeutics and unwanted immunogenicity from the bench to the bedside. The conference is aimed at accelerating development and approval of next generation biotherapeutics by adopting
SMi’s 3rd annual conference
Immunogenicity
13th and 14th June 2016, Holiday In Kensington Forum, London, UK.
Immunogenicity of an antigen is frequently encountered in the context of vaccine development, an area of intense interest currently due to the emergence or re-emergence of infectious pathogens with the potential for worldwide spread. With the global vaccine market expected to reach $84.44 billion by 2022, now is the time engage with industry experts to addresses the real challenges with immunogenicity including assay assessment, the role of aggregation, the introduction of nanobodies and many more!
For further information or to register please visit the event website www.immuno.co.uk or contact Matthew Apps on +44 (0) 207 827 6093 or mapps@smi-online.co.uk
The document discusses the key role of diagnostics in addressing the challenge of antimicrobial resistance (AMR). It makes three key points:
1) AMR is a major threat as many infections are becoming increasingly difficult to treat due to drug-resistant bacteria. Without effective antibiotics, common infections and surgeries could become life-threatening.
2) Diagnostics are critical to appropriate antibiotic use by enabling rapid and precise diagnosis of whether a bacterial or viral infection is present and, if bacterial, determining the best antibiotic to use or avoid. This can help reduce unnecessary antibiotic prescribing.
3) The document outlines a vision for AMR diagnostics in the UK to ensure rapid diagnostic technologies are universally available to guide antibiotic
This document is a program for the 3rd annual ADC Summit 2014 conference on antibody-drug conjugates taking place from May 19-21, 2014 in London. The conference will feature presentations from industry experts on topics related to developing antibody-drug conjugates, including payloads, linkers, manufacturing, and clinical trials. Attendees can learn about the latest developments and network with other professionals in the field. A pre-conference workshop on May 21st will focus on early phase development considerations for antibody-drug conjugates to support first-in-human clinical trials.
Immunotherapy Europe - The Perfect Combination of Strategy and Innovation Michael Adeniya
Phacilitate's Immunotherapy Europe will bring leaders in the field together. big phama, biotech, payers, HTAs, regulators and investors. See what's being discussed at Europe's ONLY commercial meeting for Immunotherapy!
SMi Group's 7th annual Biosimilars Europe 2016 conferenceDale Butler
This document provides information about two pre-conference workshops for the 7th Annual Biosimilars Europe conference.
The first workshop focuses on maximizing intellectual property and regulatory rights related to biosimilars. It will cover topics like regulatory data protection, orphan drug exclusivity, supplementary protection certificates, and pediatric rewards. The workshop leaders are partners at Bristows LLP.
The second workshop examines how the payer environment for biosimilars is evolving. It will provide insight into pricing, reimbursement, and formulary access processes. Case studies will also be presented on successful biosimilar launches. The workshop leader is the director of RJW & Partners Ltd, a pricing and market
SMi will host the 7th Pharmaceutical Microbiology West Coast conference on June 8-9, 2017 in San Diego, USA. The conference will address current challenges in sterility assurance, environmental monitoring, and rapid microbial methods. Over the two days, experts from companies like GSK, Amgen, Janssen, and Takeda will discuss topics like environmental monitoring trends and data analysis, challenges in endotoxin testing and sterility assurance, case studies on contamination control, and the validation and use of rapid microbial methods. Workshops on the day before will cover technologies for monitoring contamination control and case studies, as well as microbial requirements for terminal sterilization.
SMi Group's Injectable Drug Delivery 2019 conferenceDale Butler
The document advertises the 2nd Annual Injectable Drug Delivery conference taking place May 14-16, 2019 in London. The conference will focus on innovations in injectable drug formulations and devices, with sessions on formulation development, device design, manufacturing, and regulatory issues. Speakers will discuss challenges and solutions for protein formulations, digital health technologies, long-acting injectables, pre-filled syringes and more. A pre-conference workshop on use-related risk analysis in product development will also be held. Attendees can register online or by phone.
This document provides an agenda for the 2nd annual conference on immunogenicity taking place from June 29-30, 2015 in London. The conference will focus on understanding and modulating immunity in therapeutics, and exploring techniques to induce tolerance. It will include sessions on clinical directions, assays and assessments, with speakers from industry and academia. An interactive workshop on tools for early immunogenicity risk assessment will also be held on July 1.
World ADC Frankfurt 2015 - sample brochureWorld ADC
The World ADC Frankfurt meeting has been established with the simple mission of speeding up the development of more potent and safe antibody drug conjugates.
Learn not only how to make an ADC, but how to make a great one. With insights on numerous novel payload technologies, robust strategies for preclinical evaluation and emerging clinical data, there is no better opportunity to accelerate your research.
5th Annual Pre-Filled Syringes East CoastTeri Arri
This document provides an agenda for the Pre-Filled Syringes East Coast conference taking place on April 10-12, 2018 in Boston. The agenda includes workshops on human factors for connected drug delivery systems and design considerations for drug delivery outside the clinic on April 10th. The main conference on April 11-12th will feature sessions on regulatory updates, manufacturing challenges and solutions, trends toward biologics, and human factors considerations. Speakers will address topics such as syringe filling of high concentration formulations, safety evaluation of leachables, quality by design principles, and the future of digital monitoring biomarkers.
Building on the sell-out success of the launch event, SMi Group is delighted to announce the return of 3D Cell Culture, taking place on 21st and 22nd of February 2018, in London UK.
3D Cell Culture is rapidly growing with incredible potential for industrial application and a widespread reach that can be seen across many different fields, such as 3D bioprinting and microfluidics.
The 2nd annual conference will explore these overlapping areas and will combine pioneering breakthroughs with scientific research to strengthen your commercial success. Join us for exclusive insight into key topics such as disease models, organoids, organ-on-a-chip technologies, Ipsc advances and CRISPR technology. Notable speakers on the agenda for 2018 will include experts from Aurelia Bioscience, ReInnervate Ltd, Cell and Gene Therapy Catapult, University College London, Novartis Institutes for Biomedical Research, Kugelmeiers, GSK, AstraZeneca, Roche and more!
Building on almost two decades worth of expertise in fighting the growing threat of antimicrobial resistance (AMR), SMi Group are thrilled to announce the return of Superbugs and Superdrugs USA which arrives to Iselin, New Jersey on November 13th & 14th 2017.
Antimicrobial resistance has sparked an urgency in the development of new drugs as the industry strives for novel solutions to fight infectious diseases. Innovation and collaboration is requested at every level making Superbugs & Superdrugs USA, the perfect platform to strengthen knowledge in key principles such as funding incentives and global strategy, whilst honing in on clinical developments in areas such as immunotherapy, toxoid based vaccines and anti-body drug conjugates.
As methods move away from traditional small molecule antibiotics, this is critical time for AMR experts, government bodies and industry leaders, to come together and share ideas on the latest developments in treatment and prevention. Featured speakers include: Janssen, UNT Health Science Center, John Rex from CARB-X, BARDA, Pfizer, Merck, DemovaMed, Visterrra, Microbiotix more.
This document provides information about the 23rd annual Pharmaceutical Pricing and Market Access conference, which will take place on October 11-12, 2017 in London. The conference will feature workshops on drug pricing and the use of real-world evidence in market access on October 10th. Speakers will discuss topics such as collaborating with payers, patient engagement, orphan drugs, biosimilars, international reference pricing, the UK pricing landscape, value-based pricing, integrating real-world data, and reimbursement considerations for cell and gene therapies. Regulatory agencies like the FDA and HTA bodies will also present on developing market access strategies and ensuring the patient perspective.
This document provides information about the 4th annual Pre-Filled Syringes East Coast conference taking place on April 26-27, 2017 in Boston, MA. It includes details about two pre-conference workshops on human factors in prefilled devices and silicone layer technology. The conference will feature presentations from pharmaceutical companies on topics like market trends, change controls, and wearable devices. It is chaired by representatives from Shire and Regeneron and will include speakers from the FDA, AbbVie, Amgen, Eli Lilly, Janssen, Sandoz, and Biogen.
SMi's 7th annual conference on Biobanking will bring together Europe’s leading biorepositories, regulatory representatives and scientific pioneers to strengthen knowledge in biosample management as well as explore future advances in areas such as mobile bio-banking and cloud based sample management.
Understanding the ethical and regulatory framework as well as the impact of the General Data Protection Regulation (GDPR) on collaborative science in Europe will be a major focus. Plus, don’t miss keynote addresses from a selection of European biobanks currently adding value to clinical research through successful biobanking strategies including the European Sperm Bank, UK Biobank, UCL Baby Biobank, Auria Biobank and more.
Exclusive updates from the European Commission and NIBSC-MHRA, will be just some of the event highlights for 2017. Join us this June for innovative discussions through a series of interactive presentations, panel discussions and roundtables, and address relevant and critical issues on how to improve your biobanking practice.
SMi Group are thrilled to announce the return of Pre-Filled Syringes West Coast 2017 which arrives to California on June 5th & 6th.
Following on from sell-out shows in Europe and Boston, Pre-Filled Syringes West Coast will once again gather a global audience of medical device experts and PFS industry leaders to discuss new developments and showcase cutting edge advances, keeping you at the forefront of a booming industry.
The competitive PFS market has sparked great improvements as devices strive for higher quality, safety, and patient satisfaction. Innovation and excellence is requested at every level making Pre-Filled Syringes West Coast the perfect platform to strengthen knowledge in key principles such as human factor engineering, manufacturing and complex biologics, whilst honing in on emerging trends for parenteral devices, including auto injectors, pens, pumps and smart devices.
This document provides information about an upcoming conference on pain therapeutics taking place from May 22-24, 2017 in London. It summarizes the conference agenda, speakers, and topics to be discussed over the two day event and half day workshop. Key highlights include:
- The conference will focus on strategies for pain management, evaluating translation between pre-clinical and clinical studies, assessing animal models for studying pain pathways, and examining new case studies from pharmaceutical companies.
- Speakers will address topics like CGRP receptor antagonists for migraine, developing novel pain treatments, using veterinary trials to inform human research, biomarkers for pain pathways, and new therapeutic approaches for pain including Kappa opioid receptor agonists.
-
Gathering a room of Senior Scientists and Heads of Pharmaceutical Engineering, the 5th annual show provides an ideal forum to discuss the latest advancements in pharmaceutical lyophilisation, welcoming regulatory guidance from the NIBSC-MHRA and expertise from the likes of Sanofi, Boehringer Ingelheim, Roche, Novo Nordisk and more!
9th Annual Energy from Waste Conference | 8th & 9th Dec 2016Teri Arri
Now in its 9th year, Energy from Waste 2016 returns to London to discuss the latest industry updates whilst keeping attendees at the forefront of technological breakthroughs to adapt to the growing need for greener energy.
Remote Sensing and Computational, Evolutionary, Supercomputing, and Intellige...University of Maribor
Slides from talk:
Aleš Zamuda: Remote Sensing and Computational, Evolutionary, Supercomputing, and Intelligent Systems.
11th International Conference on Electrical, Electronics and Computer Engineering (IcETRAN), Niš, 3-6 June 2024
Inter-Society Networking Panel GRSS/MTT-S/CIS Panel Session: Promoting Connection and Cooperation
https://www.etran.rs/2024/en/home-english/
hematic appreciation test is a psychological assessment tool used to measure an individual's appreciation and understanding of specific themes or topics. This test helps to evaluate an individual's ability to connect different ideas and concepts within a given theme, as well as their overall comprehension and interpretation skills. The results of the test can provide valuable insights into an individual's cognitive abilities, creativity, and critical thinking skills
Travis Hills' Endeavors in Minnesota: Fostering Environmental and Economic Pr...Travis Hills MN
Travis Hills of Minnesota developed a method to convert waste into high-value dry fertilizer, significantly enriching soil quality. By providing farmers with a valuable resource derived from waste, Travis Hills helps enhance farm profitability while promoting environmental stewardship. Travis Hills' sustainable practices lead to cost savings and increased revenue for farmers by improving resource efficiency and reducing waste.
ESPP presentation to EU Waste Water Network, 4th June 2024 “EU policies driving nutrient removal and recycling
and the revised UWWTD (Urban Waste Water Treatment Directive)”
What is greenhouse gasses and how many gasses are there to affect the Earth.moosaasad1975
What are greenhouse gasses how they affect the earth and its environment what is the future of the environment and earth how the weather and the climate effects.
Current Ms word generated power point presentation covers major details about the micronuclei test. It's significance and assays to conduct it. It is used to detect the micronuclei formation inside the cells of nearly every multicellular organism. It's formation takes place during chromosomal sepration at metaphase.
The use of Nauplii and metanauplii artemia in aquaculture (brine shrimp).pptxMAGOTI ERNEST
Although Artemia has been known to man for centuries, its use as a food for the culture of larval organisms apparently began only in the 1930s, when several investigators found that it made an excellent food for newly hatched fish larvae (Litvinenko et al., 2023). As aquaculture developed in the 1960s and ‘70s, the use of Artemia also became more widespread, due both to its convenience and to its nutritional value for larval organisms (Arenas-Pardo et al., 2024). The fact that Artemia dormant cysts can be stored for long periods in cans, and then used as an off-the-shelf food requiring only 24 h of incubation makes them the most convenient, least labor-intensive, live food available for aquaculture (Sorgeloos & Roubach, 2021). The nutritional value of Artemia, especially for marine organisms, is not constant, but varies both geographically and temporally. During the last decade, however, both the causes of Artemia nutritional variability and methods to improve poorquality Artemia have been identified (Loufi et al., 2024).
Brine shrimp (Artemia spp.) are used in marine aquaculture worldwide. Annually, more than 2,000 metric tons of dry cysts are used for cultivation of fish, crustacean, and shellfish larva. Brine shrimp are important to aquaculture because newly hatched brine shrimp nauplii (larvae) provide a food source for many fish fry (Mozanzadeh et al., 2021). Culture and harvesting of brine shrimp eggs represents another aspect of the aquaculture industry. Nauplii and metanauplii of Artemia, commonly known as brine shrimp, play a crucial role in aquaculture due to their nutritional value and suitability as live feed for many aquatic species, particularly in larval stages (Sorgeloos & Roubach, 2021).
The ability to recreate computational results with minimal effort and actionable metrics provides a solid foundation for scientific research and software development. When people can replicate an analysis at the touch of a button using open-source software, open data, and methods to assess and compare proposals, it significantly eases verification of results, engagement with a diverse range of contributors, and progress. However, we have yet to fully achieve this; there are still many sociotechnical frictions.
Inspired by David Donoho's vision, this talk aims to revisit the three crucial pillars of frictionless reproducibility (data sharing, code sharing, and competitive challenges) with the perspective of deep software variability.
Our observation is that multiple layers — hardware, operating systems, third-party libraries, software versions, input data, compile-time options, and parameters — are subject to variability that exacerbates frictions but is also essential for achieving robust, generalizable results and fostering innovation. I will first review the literature, providing evidence of how the complex variability interactions across these layers affect qualitative and quantitative software properties, thereby complicating the reproduction and replication of scientific studies in various fields.
I will then present some software engineering and AI techniques that can support the strategic exploration of variability spaces. These include the use of abstractions and models (e.g., feature models), sampling strategies (e.g., uniform, random), cost-effective measurements (e.g., incremental build of software configurations), and dimensionality reduction methods (e.g., transfer learning, feature selection, software debloating).
I will finally argue that deep variability is both the problem and solution of frictionless reproducibility, calling the software science community to develop new methods and tools to manage variability and foster reproducibility in software systems.
Exposé invité Journées Nationales du GDR GPL 2024
EWOCS-I: The catalog of X-ray sources in Westerlund 1 from the Extended Weste...Sérgio Sacani
Context. With a mass exceeding several 104 M⊙ and a rich and dense population of massive stars, supermassive young star clusters
represent the most massive star-forming environment that is dominated by the feedback from massive stars and gravitational interactions
among stars.
Aims. In this paper we present the Extended Westerlund 1 and 2 Open Clusters Survey (EWOCS) project, which aims to investigate
the influence of the starburst environment on the formation of stars and planets, and on the evolution of both low and high mass stars.
The primary targets of this project are Westerlund 1 and 2, the closest supermassive star clusters to the Sun.
Methods. The project is based primarily on recent observations conducted with the Chandra and JWST observatories. Specifically,
the Chandra survey of Westerlund 1 consists of 36 new ACIS-I observations, nearly co-pointed, for a total exposure time of 1 Msec.
Additionally, we included 8 archival Chandra/ACIS-S observations. This paper presents the resulting catalog of X-ray sources within
and around Westerlund 1. Sources were detected by combining various existing methods, and photon extraction and source validation
were carried out using the ACIS-Extract software.
Results. The EWOCS X-ray catalog comprises 5963 validated sources out of the 9420 initially provided to ACIS-Extract, reaching a
photon flux threshold of approximately 2 × 10−8 photons cm−2
s
−1
. The X-ray sources exhibit a highly concentrated spatial distribution,
with 1075 sources located within the central 1 arcmin. We have successfully detected X-ray emissions from 126 out of the 166 known
massive stars of the cluster, and we have collected over 71 000 photons from the magnetar CXO J164710.20-455217.
Or: Beyond linear.
Abstract: Equivariant neural networks are neural networks that incorporate symmetries. The nonlinear activation functions in these networks result in interesting nonlinear equivariant maps between simple representations, and motivate the key player of this talk: piecewise linear representation theory.
Disclaimer: No one is perfect, so please mind that there might be mistakes and typos.
dtubbenhauer@gmail.com
Corrected slides: dtubbenhauer.com/talks.html
When I was asked to give a companion lecture in support of ‘The Philosophy of Science’ (https://shorturl.at/4pUXz) I decided not to walk through the detail of the many methodologies in order of use. Instead, I chose to employ a long standing, and ongoing, scientific development as an exemplar. And so, I chose the ever evolving story of Thermodynamics as a scientific investigation at its best.
Conducted over a period of >200 years, Thermodynamics R&D, and application, benefitted from the highest levels of professionalism, collaboration, and technical thoroughness. New layers of application, methodology, and practice were made possible by the progressive advance of technology. In turn, this has seen measurement and modelling accuracy continually improved at a micro and macro level.
Perhaps most importantly, Thermodynamics rapidly became a primary tool in the advance of applied science/engineering/technology, spanning micro-tech, to aerospace and cosmology. I can think of no better a story to illustrate the breadth of scientific methodologies and applications at their best.
The debris of the ‘last major merger’ is dynamically youngSérgio Sacani
The Milky Way’s (MW) inner stellar halo contains an [Fe/H]-rich component with highly eccentric orbits, often referred to as the
‘last major merger.’ Hypotheses for the origin of this component include Gaia-Sausage/Enceladus (GSE), where the progenitor
collided with the MW proto-disc 8–11 Gyr ago, and the Virgo Radial Merger (VRM), where the progenitor collided with the
MW disc within the last 3 Gyr. These two scenarios make different predictions about observable structure in local phase space,
because the morphology of debris depends on how long it has had to phase mix. The recently identified phase-space folds in Gaia
DR3 have positive caustic velocities, making them fundamentally different than the phase-mixed chevrons found in simulations
at late times. Roughly 20 per cent of the stars in the prograde local stellar halo are associated with the observed caustics. Based
on a simple phase-mixing model, the observed number of caustics are consistent with a merger that occurred 1–2 Gyr ago.
We also compare the observed phase-space distribution to FIRE-2 Latte simulations of GSE-like mergers, using a quantitative
measurement of phase mixing (2D causticality). The observed local phase-space distribution best matches the simulated data
1–2 Gyr after collision, and certainly not later than 3 Gyr. This is further evidence that the progenitor of the ‘last major merger’
did not collide with the MW proto-disc at early times, as is thought for the GSE, but instead collided with the MW disc within
the last few Gyr, consistent with the body of work surrounding the VRM.
The debris of the ‘last major merger’ is dynamically young
20th Annual Superbugs & Superdrugs
1. www.superbugssuperdrugs.com
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
ACADEMIC & GROUP DISCOUNTS AVAILABLE
PLUS ONE INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOP
Wednesday 21st March 2018, Copthorne Tara Hotel, Kensington, London, UK
@SMIPHARM
#smibugs
SMi present their 20th Annual Conference on…
Superbugs &
Superdrugs
Tackling the scientific, regulatory and economic
challenges to combat anti-microbial resistance
COPTHORNE TARA HOTEL, KENSINGTON, LONDON, UK
The Use of Animal Models in Pre-Clinical Drug Development
08.30 – 12.30
Workshop Leaders:
William Weiss, Director, Pre-Clinical Services, UNT System College of Pharmacy
Mark Pulse, Assistant Director, Pre-Clinical Services, UNT System College of Pharmacy
BOOK BY 30TH NOVEMBER AND SAVE £400
BOOK BY 15TH DECEMBER AND SAVE £200
BOOK BY 31ST JANUARY AND SAVE £100
CONFERENCE: 19TH - 20TH
WORKSHOP: 21ST
MAR 2018
Featuring
exclusive
MHRA
keynote
address
NEW FOR 2018:
• Analyse the current status of antimicrobial resistance with
industry led insight into current strategies to tackle AMR
• Hear exclusive case studies from a selection of
pharmaceutical companies on clinical progress
• Learn about regulatory pathways for the registration of new
antimicrobial agents
• Evaluate the latest incentives and funding solutions to spur
drug discovery
• Evaluate the latest novel alternatives to antibiotics currently in
development
CHAIRS FOR 2018:
Richard Bax, Lloyd Czaokewski,
Senior Partner, Director,
TranScrip Partners Chemical Biology Ventures
FEATURED SPEAKERS:
Cara Cassino, Chief Medical Officer and Executive Vice
President of Research and Development, Contrafect
Kathy Talkington, Project Director, Antimicrobial
Resistance, The Pew Charitable Trusts
Jean-Pierre Paccaud, Director of Business Development
and Development Strategy, GARDP, DNDi
John George, Founder/CSO,
Oppilotech
Domingo Gargallo-Viola, Chief Scientific Officer,
ABAC Therapeutics
William Weiss, Director of Pre-Clinical Services,
University of North Texas Health Science Center
Larry Sutton, Scientific Founder,
Gladius Pharmaceuticals
ATTENDEE TESTIMONIALS FROM 2017
“Very good & informative meeting”
University Medical Center Utrecht
“Good first experience. Good
to see some presentations on
novel approaches”
Immuno Research Inc
2. *Subject to final confirmation
Superbugs & Superdrugs
Day One | Monday 19th March 2018 www.superbugssuperdrugs.com
08.30 Registration & Coffee
09.00 Chairman’s Opening Remarks
Richard Bax, Senior Partner, Transcrip Partners
FUNDING & INCENTIVES
09.15 OPENING ADDRESS
GARDP: an alternative model to antibiotic drug development
• GARDP is a not-for-profit R&D organisation developing new
treatments to tackle durg-resistant bacterial infections , and
aiming at delivering them in a responsible, sustainable and
accessible manner
• Public-private partnerships contributions to fight AMR:
collaboration and complementarity
• Experimenting alternative business models to deliver innovation
• Current programs and deals will be presented
Dr Jean-Pierre Paccaud, Director of Business Development
and Development Strategy, GARDP, DNDi
09.55 KEYNOTE ADDRESS
Tackling the current lack of incentives for people working in
antimicrobial resistance research and development
• Analysis of the economic issues which affect the research
and development of new antibiotics in the private sector?
• Using ‘risk-sharing’ arrangements between health care payers
and pharmaceutical companies to drive new development
• Which push incentives are the most beneficial and could
similar results be achieved using relevant pull incentives?
• How to ensure that financial incentives for the private sector,
does not prevent drug accessibility to developing countries?
Adrian Towse, Director, Office of Health Economics*
10.35 Morning Coffee
STRATEGIES TO RESURRECT PATHOGEN SENSITIVITY TO ANTIBIOTICS
11.05 Bacterial cybergenetics to resurrect sensitivity to antibiotics in
anti-microbial resistant (AMR) pathogens
• “Nemesis Symbiotics” use programmable RNA-guided DNA
endonuclease gene editing technology to target antibiotic
resistance genes
• A single Symbiotic inactivates members of multiple families
of resistance genes –so resurrecting sensitivity to antibiotics
• Pre-clinical studies show that Transmids, our novel vectors,
deliver Symbiotics to bacteria by phage-coat infection and
subsequently spread by bacterial conjugation
• Symbiotics are biological companion therapeutics to be
used together with well-established antibiotics for both
therapeutic treatment of infection as well as prophylactic
treatment preventing the spread of AMR
Conrad Lichtenstein, Chief Scientific Officer, Nemesis Bioscience
11.45 Using immune modulation alongside antibiotics to counter
multidrug-resistant bacteria
• The antibiotic field can arguably learn from oncology where
immune modulation used alongside chemotherapy has
transformed treatment prospects
• Similarly, to beat resistant bacteria, we need to counter the
way they usurp our immune defenses to evade antibiotics
• Summarising novel ideas on using immune modulation
alongside antibiotics to beat resistant species
• Suggesting that adding a third component could reduce
death rates from sepsis which remain very high even with
use of modern antibiotics
David Brown, Managing Director and Founder,
Alchemy Biomedical Consulting
12.25 Networking Lunch
STRATEGIES TO ASSIST THE DEVELOPMENT OF NEW THERAPEUTICS & DRUGS
KEYNOTE ADDRESS
13.35 SPARKing New Antibiotic Discovery
– the Shared Platform for Antibiotic Research and Knowledge
• The Shared Platform for Antibiotic Research and Knowledge
is a groundbreaking and dynamic information-sharing platform
• Bringing together curated antibiotic discovery data and
cutting-edge analytics to help scientists tackle the scientific
barriers blocking antibiotic discovery
• While the global threat of antibiotic resistance continues
to rise, nearly every antibiotic in use today is based on a
discovery from more than 30 years ago
• SPARK will focus on the unique challenges of finding
and designing antibiotics that can defeat drug-resistant
Gram-negative bacteria, which are among the
hardest-to-treat superbugs
Kathy Talkington, Project Director, Antimicrobial Resistance,
The Pew Charitable Trusts
14.15 Use of the PasNas platform to enable high quality
antibacterial hit finding
• The infectious diseases drug discovery is enormously
inefficient. We can not repeat things over and over again.
What can we do to change this trend?
• Disruptive Innovation to control risk factors, improve
efficiency and ensure delivery
• New paradigms in infectious diseases, from magic bullet
to precision antibacterial agents
Domingo Gargallo-Viola, Chief Scientific Officer,
ABAC Therapeutics
14.55 Afternoon Tea
15.25 Building a detailed computational network model of cell
envelope biogenesis: a systems biology approach to
developing antibacterial drugs (potentiators)
• Model incorporates the synthesis of key components
including LPS, phospholids and peptidoglycan
• The model is used to guide the identification of potentiator
targets– agents that can enhance the activities of existing
antibiotics
• Potentiator programmes derived from model
John George, Founder/CSO, Oppilotech
16.05 Teaching old cephalosporin dogs new mechanistic tricks
against MDR Gram-negative bacteria
• Cephalosporin synthetic scaffolding for new mechanisms
• In vitro activity versus WHO critical priority pathogens
• Comparison to new combination ß-lactams
• In vivo performance
Larry Sutton, Scientific Founder, Gladius Pharmaceuticals
16.45 Novel virulence factors of Acinetobacter baumannii as targets
for antibacterial development
• Over the past 3-4 years, my team has exploited a transposon
mutant library to identify targets required for A. baumannii
virulence in animal models of infection
• Some of these genes/proteins are novel targets on the
surface of the bacterium that we are currently developing
human monoclonal antibodies against
• We have also identified some targets within the bacterium
that could be drug-able
• As we learn and test more, we believe the true strength of
our research is not a single attack against the bacteria, but
rather a combination of multiple drugs/antibodies against
different targets to render the bacteria avirulent and
cleared by the immune system
Daniel Zurawski, Head, Antibacterial Discovery and
Development, Walter Reed Army Institute of Research
(WRAIR)/Bacterial Diseases Branch
17.25 Chairman’s Closing Remarks and Close of Day One
Welcome Letter from our 2018 Chairs
Dear Colleagues,
It is with great pleasure that we welcome you to participate in the
20th Annual Superbugs & Superdrugs Conference taking place on
19th - 20th March 2018, Central London, UK.
We are delighted to chair this annual industry meeting in 2018 again, which
will gather a high level of international experts and project decision makers
to review the successes of 2017 and look to the future of AMR.
This year’s conference has an exciting mix of traditional and alternative
approaches, industry and academia, funders and regulators.
Yours Sincerely,
Richard Bax,
Senior Partner,
TranScrip Partners
Lloyd Czaplewski,
Director,
Chemical Biology
Ventures
Register online at www.superbugssuperdrugs.com
SPONSORSHIP AND EXHIBITION OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy.
Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion
specific to your industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call:
Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk
Official Media Partners
3. Superbugs & Superdrugs
www.superbugssuperdrugs.com Day Two | Tuesday 20th March 2018
Supported by
Alternatively fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
MARKETING OPPORTUNITIES
Want to know how you can get involved? Interested in promoting your services to this market?
Contact – Teri Arri SMi Marketing on +44 (0) 20 7827 6162 or email: tarri@smi-online.co.uk
08.30 Registration & Coffee
09.00 Chairman’s Opening Remarks
Lloyd Czaplewski, Director, Chemical Biology Ventures
OPENING ADDRESS
09.10 Highlights from the Traditional and Alternative Antibacterial
Pipeline
• What new therapies can we anticipate?
• Research challenges
• Are we asking the right questions?
Lloyd Czaplewski, Director, Chemical Biology Ventures
REGULATIONS & CONSIDERATIONS
KEYNOTE ADDRESS
09.50 Regulatory considerations for the registration of new
antibacterial agents
• Ensuring that candidate antibacterial agents with potential
to address an unmet need are evaluated in line with
regulatory guidance
• Options for clinical development programmes
• Importance of the pharmacokinetic-pharmacodynamic
relationship
• Update on recent guidance and planned revisions to EMA
guidance
Mair Powell, Medical Assessor, MHRA
10.30 Morning Coffee
RESEARCH ADVANCES IN ANTIBIOTIC DEVELOPMENT
KEYNOTE ADDRESS
11.00 Iclaprim: a well differentiated, targeted, potent and rapidly
bactericidal antibiotic against multidrug resistant bacteria
• Exploring a novel mechanism of action different from any
other antibiotic currently in development
• Positive clinical outcomes among patients with ABSSSI
and HAP/VAP through optimizing iclaprim’s dose and the
concentration at sites of infection
• Looking into safety data and what lies ahead to achieve
FDA and EMA approval
David Huang, Chief Medical Officer, Motif BioSciences, Inc
11.40 Opening up new opportunities for the treatment of infectious
diseases using nanoformulations
• Nanoformulations formulate drugs into nanoparticles
and can greatly enhance their pharmacokinetic and
pharmacodynamics properties
• Exploring the potential of novel drug nanoformulations to
create new treatments for infections
• Presentation of research and discussion of the potential of
nanoformulations more broadly in infectious disease
David Cook, Chief Scientific Officer,
Blueberry Therapeutics Ltd.
12.20 Networking Lunch
13.20 Challenges in Antimicrobial Evaluation of Novel Therapies
using Animal Models
• Where to start / What model to use
• Dose / Regimen – How to choose
• Test articles with no intrinsic activity
• How to evaluate combination therapy
• What does the data tell us?
William Weiss, Director of Pre-Clinical Services,
University of North Texas Health Science Center
NOVEL CANDIDATES AND ALTERNATIVES TO ANTIBIOTICS
KEYNOTE ADDRESS
14.00 Lysins: Alternative Antimicrobials to Improve Clinical
Outcomes Serious Bacterial Infections - CF-301 - A Case Study
• CF-301 demonstrates the hallmark features of lysins,
including: rapid, targeted bacteriolysis, potent synergy with
conventional antibiotics, activity against antibiotic-resistant
strains, low propensity for resistance and remarkable biofilm
eradication, which make lysins attractive therapeutic
candidates for serious bacterial infections.
• In vivo studies with CF-301 signal the therapeutic potential
of lysins boost the efficacy of conventional antibiotics and
combat antimicrobial resistance
• The ongoing CF-301 clinical development program will help
define the place in therapy for ability of lysin therapeutics in
the treatment of serious, invasive,
biofilm-dependent bacterial infections is being evaluated in
clinical development
Cara Cassino, Executive Vice President of Research and
Development and Chief Medical Officer,
Contrafect Corporation
14.40 Afternoon Tea
15.10 C. auris – a difficult to treat, emerging pathogen
• Brief history of C. auris
• How C. auris differs from other candida species
• Experimental models of C. auris
• New potential treatments
Stephen A. Barat, Head of Pre-Clinical Research and Early
Clinical Development, Scynexis
15.50 Amelioration of multi drug resistant infection by antibody
modulation
• Some individuals overproduce antibody that recognises
surface structures on bacteria
• Such antibody interferes with serum killing of the bacterium
• Removal of these antibodies by apharesis restores serum
killing
• Restoration of serum killing is associated with clinical
improvement
Ian R. Henderson, Professor of Microbial Biology,
Director, Institute of Microbiology and Infection,
University of Birmingham
16.30 Chairman’s Closing Remarks and Close of Day Two
4. The Use of Animal Models in Pre-Clinical
Drug Development
Workshop Leaders:
William Weiss, Director, Pre-Clinical Services,
UNT System College of Pharmacy
Mark Pulse, Assistant Director, Pre-Clinical Services,
UNT System College of Pharmacy
HALF-DAY POST-CONFERENCE WORKSHOP
Wednesday 21st March 2018
08.30 – 12.30
Copthorne Tara Hotel, Kensington, London, UK
Overview of Workshop:
The workshop will provide an overview of the use of animal
models in preclinical drug development. We will focus on the
transition from in vitro activity to in vivo efficacy, the choice of
the right animal model for proof of concept studies, provide
examples of relevant animal models with supportive data and
interpretation of results as they relate to the clinical condition.
Reason to attend:
• To gain an understanding of what animal models can and
cannot provide
• To learn how animal model endpoints relate to clinical
endpoints
• In depth discussion of how models are performed
• Regulations and constraints in the performance of these
models
Programme:
08.30 Registration & Coffee
09.00 Preclinical Animal Models
• Opening remarks and introduction
• History of animal testing
• The general use of animals in research
• Are animal models predictive?
09.30 Experimental Design and Methodology
• How to design the most relevant study for your needs
• Factors that need to be considered – Before, during
and after
• Realistic objectives - What you can and can’t do
• Advantages and Disadvantages
10.30 Morning Coffee
11.00 Animal Models – Examples
• Clinical relevance of current models
• Acute and chronic infection models – From
bacteremia to pneumonia
• GI related infections
• Implanted device infections
• Antifungal testing
• Pharmacokinetics / Pharmacodynamics
12.00 Ethical Use of Animals in Research
• Oversight of animal use in biomedical research
• IACUC – Friend or Foe?
• Governing agencies and regulations for animal
models
• Replace / Refine / Reduce
12.30 Final discussion and close of Workshop
About the Workshop Leaders:
William Weiss Before leading the PreClinical Services
group, Bill was Director of Drug Evaluation at
Cumbre Pharmaceuticals Inc. and a Group Leader
in Infectious Disease Discovery Research at Wyeth
Research (Pfizer), Lederle Laboratories and Schering-Plough
(Merck). His current responsibilities included leading in vitro
and in vivo evaluation of novel test articles from medicinal
synthetic and natural products chemistry. He has worked on
numerous antibacterial programs including the development
of Suprax, Zosyn and Tygacil. His expertise encompasses the
development of animal research models, evaluation of new
and novel therapeutic agents as well as pharmacokinetic /
pharmacodynamic analysis.
Mark Pulse Mark holds a Masters of Science degree
in molecular microbiology and immunology and
his early research at the University of North Texas
Health Science Center primarily focused on bacterial
pathogenesis and pre-clinical drug evaluation within in vivo
models. For the last 12 years he has been directly involved
in the development of multiple in vivo models that have
included GI- and respiratory-associated infectious diseases,
device-associated (biofilm) infections and pharmacokinetic
studies within multiple animal species. He also has experience
with survival surgery in multiple animal models, including USDA
species.
About the organisation:
The Pre-Clinical Services group at the University of North Texas
Health Science Center conducts studies utilizing established
models of both acute and chronic bacterial infections in
several different animal species. UNTHSC Pre-clinical Services
together has over 33 years of pharmaceutical and specialized
biotech experience in the performance of therapeutic
efficacy models and drug discovery / development. The group
uses this experience to guide the drug discovery process,
through protocol design, implementation and analysis for
compound lead selection.
5. SPONSORSHIP AND EXHIBITION OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising and
branding packages, uniquely tailored to complement
your company’s marketing strategy. Prime networking
opportunities exist to entertain, enhance and expand
your client base within the context of an independent
discussion specific to your industry. Should you wish to
join the increasing number of companies benefiting
from sponsoring our conferences please call:
Alia Malick on +44 (0) 20 7827 6168 or
email: amalick@smi-online.co.uk
NOVEMBER 2017
Superbugs &
Superdrugs USA
13th - 14th November 2017
New Jersey, USA
Pharmaceutical
Microbiology East Coast
13th - 14th November 2017
New Jersey, USA
Biosimilars North America
15th - 16th November 2017
New Jersey, USA
Lyophilization USA
16th - 17th November 2017
New Jersey, USA
Ophthalmic Drugs
28th - 29th November 2017
London, UK
DECEMBER 2017
Cold Chain Distribution
13th - 14th December 2017
London, UK
JANUARY 2018
Pre-Filled Syringes Europe
17th - 18th January 2018
London, UK
Pharmaceutical
Microbiology
22nd - 23rd January 2018
London, UK
Social Media in the
Pharmaceutical Industry
22nd - 23rd January 2018
London, UK
FEBRUARY 2018
Parallel Trade
6th - 7th February 2018
London, UK
3D Cell Culture
21st - 22nd February 2018
London, UK
RNA Therapeutics
21st - 22nd February 2018
London, UK
MARCH 2018
Superbugs & Superdrugs
19th - 20th March 2018
London, UK
Paediatric Clinical Trials
19th - 20th March 2018
London, UK
Drug Discovery
21st - 22nd March 2018
London, UK
Controlled Release
Delivery
21st - 22nd March 2018
London, UK
APRIL 2018
Antibodies and Antibody
Drug Conjugates
9th - 10th April 2018
London, UK
Adaptive Designs
in Clinical Trials
9th - 10th April 2018
London, UK
Asthma & COPD
11th - 12th April 2018
London, UK
Pre-Filled Syringes
East Coast
11th - 12th April 2018
Boston, MA
MAY 2018
Pharmaceutical Freeze
Drying Technology
9th - 10th May 2018
London, UK
Injectable Drug Delivery
16th - 17th May 2018
London, UK
Pain Therapeutics
21st - 22nd May 2018
London, UK
Highly Potent Active
Pharmaceutical
Ingredients
21st - 22nd May 2018
London, UK
Drug Safety
23rd - 24th May 2018
London, UK
JUNE 2018
Pre-Filled Syringes
West Coast
4th - 5th June 2018
San Diego, CA
Pharmaceutical
Microbiology West Coast
7th - 8th June 2018
San Diego, CA
ADMET
11th - 12th June 2018
London, UK
Molecular Diagnostics
13th - 14th June 2018
London, UK
BioBanking
13th - 14th June 2018
London, UK
SMi Pharmaceutical
Forward Planner
6. Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Payment: If payment is not made at the time of booking, then an invoice will be issued and must
be paid immediately and prior to the start of the event. If payment has not been received then
credit card details will be requested and payment taken before entry to the event. Bookings within
7 days of event require payment on booking. Access to the Document Portal will not be given until
payment has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send
a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge,
providing that cancellation is made in writing and received at least 28 days prior to the start of the
event. Regretfully cancellation after this time cannot be accepted. We will however provide the
conferencesdocumentationviatheDocumentPortaltoanydelegatewhohaspaidbutisunable
to attend for any reason. Due to the interactive nature of the Briefings we are not normally able
to provide documentation in these circumstances. We cannot accept cancellations of orders
placed for Documentation or the Document Portal as these are reproduced specifically to order.
If we have to cancel the event for any reason, then we will make a full refund immediately, but
disclaim any further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection
Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about
other products and services. Unless you tick here □ we may also share your data with third parties
offeringcomplementaryproductsorservices.Ifyouhaveanyqueriesorwanttoupdateanyofthe
data that we hold then please contact our Database Manager databasemanager@smi-online.
co.uk or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your
address on the attached letter.
Payment must be made to SMi Group Ltd, and received before the event, by one of the
following methods quoting reference P-237 and the delegate’s name. Bookings made within
7 days of the event require payment on booking, methods of payment:
□ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
□ Cheque We can only accept Sterling cheques drawn on a UK bank.
□ Credit Card □ Visa □ MasterCard □ American Express
All credit card payments will be subject to standard credit card charges.
Card No: □□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
Card Billing Address (If different from above):
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged
on Document portal and literature distribution for all UK customers and for those EU
Customers not supplying a registration number for their own country here.
______________________________________________________________________________________
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email events@smi-online.co.uk
EARLY BIRD
DISCOUNT
I would like to attend: (Please tick as appropriate) Fee Total
□ Conference & Workshop £2098.00 + VAT £2517.60
□ Conference only £1499.00 + VAT £1798.80
□ Workshop only £599.00 + VAT £718.80
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
literature to all conference attendees £999.00 + VAT £1198.80
The conference fee includes refreshments, lunch, conference papers, and access to
the Document Portal. Presentations that are available for download will be subject to
distribution rights by speakers. Please note that some presentations may not be available
for download. Access information for the document portal will be sent to the e-mail
address provided during registration. Details are sent within 24 hours post conference.
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: events@smi-online.co.uk or fax +44 (0) 870 9090 712
I cannot attend but would like to purchase access to the following
Document Portal/paper copy documentation Price Total
□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations – paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
Unique Reference Number
Our Reference LVP-237
DELEGATE DETAILS
Terms and Conditions of Booking
PAYMENT
VAT
CONFERENCE PRICES
DOCUMENTATION
VENUE CopthorneTaraHotel,Kensington,ScarsdalePlaceKensingtonLondon,W85SR,UK
SUPERBUGS & SUPERDRUGS
Conference: Monday 19th & Tuesday 20th March 2018, Copthorne Tara Hotel, Kensington, London, UK
Workshop: Wednesday 21st March 2018, London, UK
4 WAYS TO REGISTER
www.superbugssuperdrugs.com
FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
POST your booking form to: Events Team, SMi Group Ltd,
1 Westminster Bridge Road, London, SE1 7XW
□ Book by 30th November to receive £400 off the conference price
□ Book by 15th December to receive £200 off the conference price
□ Book by 31st January to receive £100 off the conference price